Harbin Pharmaceutical Group Co Ltd banner

Harbin Pharmaceutical Group Co Ltd
SSE:600664

Watchlist Manager
Harbin Pharmaceutical Group Co Ltd Logo
Harbin Pharmaceutical Group Co Ltd
SSE:600664
Watchlist
Price: 3.58 CNY -2.72% Market Closed
Market Cap: ¥9B

P/E

20.1
Current
21%
More Expensive
vs 3-y average of 16.5

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
20.1
=
Market Cap
¥10.5B
/
Net Income
¥449.2m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
20.1
=
Market Cap
¥10.5B
/
Net Income
¥449.2m

Valuation Scenarios

Harbin Pharmaceutical Group Co Ltd is trading above its 3-year average

If P/E returns to its 3-Year Average (16.5), the stock would be worth ¥2.95 (18% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-18%
Maximum Upside
+48%
Average Upside
10%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 20.1 ¥3.58
0%
3-Year Average 16.5 ¥2.95
-18%
5-Year Average 16.8 ¥3
-16%
Industry Average 25.5 ¥4.55
+27%
Country Average 29.6 ¥5.28
+48%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
¥10.5B
/
Oct 2025
¥449.2m
=
20.1
Current
¥10.5B
/
Dec 2025
¥661.4m
=
15.9
Forward
¥10.5B
/
Dec 2026
¥763.1m
=
13.8
Forward
¥10.5B
/
Dec 2027
¥864.9m
=
12.1
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Peer Comparison

Market Distribution

In line with most companies in China
Percentile
36th
Based on 5 557 companies
36th percentile
20.1
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

Harbin Pharmaceutical Group Co Ltd
Glance View

Market Cap
9B CNY
Industry
Pharmaceuticals

Founded amidst the industrial boom of the 1950s, Harbin Pharmaceutical Group Co., Ltd. has evolved into one of China's pharmaceutical giants, headquartered in Harbin, Heilongjiang Province. Historically grounded in traditional Chinese medicine, it has grown into a multifaceted enterprise that blends its cultural heritage with modern pharmaceutical science. Harbin Pharma's journey from its humble beginnings to becoming a household name is marked by its robust research and development efforts, which are key to its operations. The company's vertical integration strategy stretches through the entire pharmaceutical value chain, encompassing research, production, and distribution, thereby optimizing efficiency and maintaining quality control across its vast product lines. This structure not only helps minimize costs but also allows Harbin Pharma to quickly adapt to changes in the healthcare market. The company primarily generates revenue through the production and sale of both prescription and over-the-counter drugs, catering to a diverse array of health needs globally. A significant portion of its income stems from the manufacture of antibiotics, patent drugs, and biological products, though it also maintains a strong presence in the consumer health sector with vitamins and dietary supplements. Strategically, Harbin Pharma leverages its extensive distribution network, one of the largest in China, ensuring that its products reach even the most remote areas. Moreover, the company benefits from partnerships and collaborations with international pharmaceutical companies, which allow it to expand its global footprint and enhance its product offerings. In essence, Harbin Pharmaceutical Group's success is anchored in its adaptive business strategies, commitment to innovation, and ability to navigate the complexities of the rapidly evolving pharmaceutical landscape.

Intrinsic Value
5.94 CNY
Undervaluation 40%
Intrinsic Value
Price ¥3.58
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett